Immunogenicity of Recombinant Human Interferon Beta Interacting with Particles of Glass, Metal, and Polystyrene

2012 ◽  
Vol 101 (1) ◽  
pp. 187-199 ◽  
Author(s):  
Miranda M.C. Van Beers ◽  
Francesca Gilli ◽  
Huub Schellekens ◽  
Theodore W. Randolph ◽  
Wim Jiskoot
Keyword(s):  
Interferon Beta ◽  
Human Interferon ◽  
Recombinant Human Interferon Beta ◽  
Glass Metal

Recombinant human interferon- in the treatment of condylomata acuminata

1997 ◽  
Vol 8 (10) ◽  
pp. 622-628 ◽  
Author(s):  
Wallace Dinsmore ◽  
Joe Jordan ◽  
Colm O'Mahony ◽  
John R W Harris ◽  
Alexander McMillan ◽  
...  
Keyword(s):  
Interferon Beta ◽  
Cytopathic Effect ◽  
Treatment Success ◽  
Condylomata Acuminata ◽  
Human Interferon ◽  
Partial Reduction ◽  
Benign Lesions ◽  
Previous Therapy ◽  
Patient Withdrawal ◽  
Recombinant Human Interferon Beta

The number of clinic consultations for condylomata acuminata (genital warts) has increased substantially during the last 30 years. Most infections produce benign lesions but a few types may be associated with cervical and penile cancers. Interferons (IFN) have shown antiviral properties to these infections and IFN- in particular has demonstrated a specific cytopathic effect in humans. A total of 124 patients with condylomata acuminata, the majority of whom had failed previous therapy, were treated intralesionally with either recombinant human interferon-beta 1a (r-hIFN--1a) or placebo. Up to 6 lesions were treated in each patient, and injections were made 3 times per week for a total of 9 injections. The patients were then followed up for 3 months. Efficacy assessments at all time points (day 19, week 6 and month 3) showed a clear advantage for the r-hIFN--1a interferon-beta treatment. Patients receiving rhIFN--1a showed a greater proportion of treatment success in terms of the complete or partial reduction (at least 50%) of the total area of the treated lesions. The treatment was also well tolerated. Headache, flu-like symptoms and asthenia were more common in patients receiving r-hIFN--1a, but these adverse events were generally mild in severity and rarely led to patient withdrawal. It was concluded that r-hIFN--1a has good efficacy in condylomata acuminata, and therefore presents a useful therapeutic alternative in this hard-to-treat condition.

Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates

2016 ◽  
Vol 36 (4) ◽  
pp. 247-257 ◽  
Author(s):  
Mohadeseh Haji Abdolvahab ◽  
Ahmad Fazeli ◽  
Andhyk Halim ◽  
Ahmad S. Sediq ◽  
Mohammad Reza Fazeli ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Interferon Beta ◽  
Human Interferon ◽  
Immune Tolerant ◽  
Recombinant Human Interferon Beta
Sign in / Sign up

Export Citation Format

Share Document